Screener
Skye Bioscience
SKYESkye Bioscience, Inc. is a clinical-stage biotechnology company focused on developing next-generation molecules that modulate G-protein-coupled receptors (GPCRs).
$6.95M-93.7%
Earnings
Next report
Nov 9, 2026 (in 2 months)EPS estimate-$1.14
Competitors
By market cap
By revenue growth
Profile
Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on developing next-generation molecules that modulate G-protein-coupled receptors (GPCRs). The company's primary value proposition lies in pioneering peripherally restricted antibodies to treat obesity, overweight, and metabolic disorders with improved safety and tolerability compared to existing therapies.
Competitive position
Skye is a clinical-stage innovator targeting the CB1 receptor with a peripherally restricted antibody, aiming to differentiate from GLP-1 therapies by improving lean muscle mass retention and tolerability.
GeographiesGlobal
Customer segmentsPatients, Healthcare providers
Business modelR&D intensive, Biotechnology drug development
SuppliersContract research organizations, Specialized antibody manufacturing, Clinical trial sites
CustomersSpecialty pharmacies, Hospitals, Metabolic health clinics
CountryUnited States of America
Listed2014
Employees11.0
CEOPunit Dhillon
SectorHealthcare
IndustryBiotechnology
Websiteskyebioscience.com
FilingsSEC EDGAR
FAQ
- What is Skye Bioscience's market cap?
- Skye Bioscience (SKYE) has a market capitalization of $7.0M and trades on NASDAQ.
- Who are Skye Bioscience's competitors?
- Skye Bioscience's key competitors include Eli Lilly and Company, Biomea Fusion, Inc. Common Stock, Palatin Technologies, Inc., and others. These companies compete in similar markets and product categories.
- What subsidiaries does Skye Bioscience have?
- Skye Bioscience's subsidiaries include Bird Rock Bio, Inc..
- Where is Skye Bioscience headquartered?
- Skye Bioscience is headquartered in United States of America and employs approximately 11 people. It has been publicly traded since 2014.